Janux Therapeutics, Inc. — Q1 2022 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three months ended March 31, 2022. Janux is a preclinical-stage biopharmaceutical company developing cancer immunotherapies using its TRACTr and TRACIr platforms. It has no approved products and has generated no product-sales revenue; collaboration revenue is from its Merck agreement.
Key financial metrics
Amounts below are in millions of U.S. dollars, except per-share data.
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Collaboration revenue | $1.589 | $0.380 |
| Research and development expense | $10.184 | $1.925 |
| General and administrative expense | $4.947 | $0.739 |
| Operating loss | $(13.542) | $(2.284) |
| Net loss | $(13.410) | $(2.284) |
| Comprehensive loss | $(14.977) | $(2.284) |
| Basic and diluted net loss per share | $(0.32) | $(2.06) |
| Net cash used in operating activities | $(11.522) | Net cash provided of $5.563 |
- At March 31, 2022, cash and cash equivalents were $55.129 million, short-term investments $306.071 million, and restricted cash $0.816 million. Together these totaled approximately $362.0 million; restricted cash is not available for general use.
- Total assets were $368.597 million and total liabilities $12.515 million. The balance sheet reports no debt. Stockholders’ equity was $356.082 million; accumulated deficit was $60.821 million.
- Q1 investing cash inflow of $31.068 million mainly reflected net maturities of short-term investments, not operating cash generation. Financing cash flow was immaterial.
- Gross margin is not meaningful for this pre-revenue company; the filing does not report product sales or product gross profit.
Material changes versus the prior comparable period
- Revenue increased by $1.209 million, which management attributed to more full-time-equivalent research hours under the Merck collaboration.
- R&D expense increased by $8.259 million, principally from platform and program development, personnel and facilities, and stock-based compensation. G&A expense rose by $4.208 million, driven mainly by stock-based compensation, personnel and public-company costs.
- Net loss widened by $11.126 million as operating expenses increased. Stock-based compensation was $3.958 million, compared with $0.123 million a year earlier.
- Available-for-sale investments recorded a $1.567 million unrealized loss in other comprehensive income, attributed primarily to economic conditions and interest-rate changes rather than credit factors. No credit-loss allowance or realized investment gains or losses was recorded.
Outlook, management commentary, risks and unusual items
- Management expects substantial operating losses and higher R&D and G&A spending for the foreseeable future. It believes available cash, cash equivalents and investments are sufficient for at least 12 months from the report’s issuance, but says additional capital will be needed to advance programs and that financing may not be available on acceptable terms.
- The company reported submitting an IND for PSMA-TRACTr (JANX007); it expected an IND for EGFR-TRACTr (JANX008) in the second half of 2022, and IND submissions for TROP2-TRACTr and the PD-L1×CD28 TRACIr candidate in 2023. The programs were described as preclinical or discovery-stage, and the company had not begun human clinical trials.
- Merck selected the second collaboration target in May 2022, after quarter-end, triggering an $8.0 million payment obligation to Janux. At March 31, deferred revenue under the collaboration was $4.649 million, all current. Merck has discretion to stop or terminate the collaboration; future milestones and royalties are contingent.
- A noncancelable office and laboratory lease was expected to commence in July 2022, with a 126-month term and approximately $37.7 million of estimated undiscounted payments. The related lease liability was not yet recorded at March 31 because the lease had not commenced.
- Key risks include early-stage development and uncertain clinical/regulatory outcomes; dependence on third-party research and manufacturing; the need for future financing; potential safety risks associated with T-cell engagers; reliance on Merck for collaboration revenue; and intellectual-property, competition, COVID-19, and market risks. The company reported no material legal proceedings and said disclosure controls were effective. A new ERP system was implemented in Q1, with related control changes.
Important facts for investors to verify
- Confirm the current status and timing of JANX007’s IND and the stated development timelines for JANX008, TROP2-TRACTr and TRACIr.
- Track receipt and accounting treatment of Merck’s $8.0 million second-target payment, remaining research obligations, and any later milestones or target decisions.
- Assess cash burn, investment values and interest-rate exposure against the company’s stated runway, including the planned laboratory lease and rising development costs.
- Monitor dilution from equity compensation and future financing: 7.122 million stock options were outstanding at March 31, and additional shares were reserved under equity plans.
- Evaluate whether preclinical safety and efficacy findings translate to human trials, and whether manufacturing, intellectual-property and regulatory risks affect program timelines.